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The causal relationship between atrazine exposure and the
occurrence of breast cancer in women was evaluated using the
framework developed by Adami et al. (2011) wherein biological
plausibility and epidemiological evidence were combined to
conclude that a causal relationship between atrazine exposure and
breast cancer is ‘‘unlikely’’. Carcinogenicity studies in female
Sprague-Dawley (SD) but not Fischer-344 rats indicate that high
doses of atrazine caused a decreased latency and an increased
incidence of combined adenocarcinoma and ﬁbroadenoma mam-
mary tumors. There were no effects of atrazine on any other tumor
type in male or female SD or Fischer-344 rats or in three strains of
mice. Seven key events that precede tumor expression in female SD
rats were identiﬁed. Atrazine induces mammary tumors in aging
female SD rats by suppressing the luteinizing hormone surge,
thereby supporting a state of persistent estrus and prolonged
exposure to endogenous estrogen and prolactin. This endocrine
mode of action has low biological plausibility for women because
women who undergo reproductive senescence have low rather than
elevated levels of estrogen and prolactin. Four alternative modes of
action (genotoxicity, estrogenicity, upregulation of aromatase gene
expression or delayed mammary gland development) were consid-
ered and none could account for the tumor response in SD rats.
Epidemiological studies provide no support for a causal relationship
between atrazine exposure and breast cancer. This conclusion is
consistent with International Agency for Research on Cancer’s
classiﬁcation of atrazine as ‘‘unclassiﬁable as to carcinogenicity’’
and the United States Environmental Protection Agency’s classiﬁ-
cation of atrazine as ‘‘not likely to be carcinogenic.’’
Key Words: atrazine; mode of action; endocrine; breast cancer;
weight-of-the-evidence; framework.
Toxicology is rapidly being transformed from a descriptive
science to one capable of prediction. Central to this progress
is the understanding of key genomic, proteomic, biochemical,
physiological, and pathological events on the pathway from
chemical exposure to the expression of toxicity. The succession
of key events following initial exposure, through intermediate
states and ultimately to measurable adverse outcomes has been
called a ‘‘mode of action’’ (Meek et al., 2003; Sonich-Mullin
et al., 2001; USEPA, 2005). When the sequence of events is
understood at a fundamental level of chemical-cell molecular
interaction, the mode of action becomes a mechanism of
toxicity. Mechanisms of toxicity are often postulated but in fact
are rarely established. In the expression of toxicity, it is not
uncommon for different facets of toxicity to be triggered at
different dose levels (Slikker et al., 2004a,b) or through
differentmechanisms.Furthermore,differencesbetweenspecies
withrespecttoabsorption,distribution,metabolism,elimination,
and target-speciﬁc susceptibility may render the extrapolation
from in vitro models or even from in vivo animal data to humans
difﬁcult.
To accommodate the complexity of evaluating a mode of
action, systematic approaches have been developed to evaluate
the relevance of ﬁndings in animal studies to humans (Meek
et al.,2 0 0 3 ). Three key questions are: (1) Is there sufﬁcient
evidence in animal studies to propose a mode of action? (2) Is
that mode of action operative in humans? and (3) Is the mode of
action relevant to humans after considering differences between
species with respect to pharmacokinetic and toxicodynamic
factors operative at expected levels of human exposures?
Ultimately, the question of whether humans display toxicity
following exposure to the chemical through ingestion, in-
halation, or dermal contact can best be ascertained from
observational epidemiology. Although there is a long history of
interpreting epidemiology studies, only recently have methods
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data from observational epidemiology (Adami et al., 2011;
European Center for Ecotoxicology and Toxicology of
Chemicals, 2009; Swaen, 2006). This paper presents a case
study utilizing the methodology described by Adami et al.
(2011) wherein toxicological and epidemiological evidence
were combined in a systematic framework to conclude whether
a causal relationship exists between atrazine exposure and
breast cancer in humans. Mode of action research using animal
models (Brusick, 1994; Cooper et al., 2007; Eldridge and
Wetzel, 2008; Stevens et al., 1994; Yi, Simpkins, and
Breckenridge, in preparation) and epidemiology studies on
breast cancer in women were evaluated. Breast cancer was
selected for this case study because there were many mode of
action research studies and a number of epidemiological
studies on breast cancer that have been previously evaluated by
regulatory authorities as part of a comprehensive cancer risk
assessment (Australian Pesticides and Veterinary Medicines
Authority [APVMA], 2004, 2008; Food and Agricultural
Organization of the United Nations and the World Health
Organization [FAO/WHO], 2009; USEPA, 2003b, 2006). A
detailed review of the association between triazine exposure
and any cancer has also just recently been published
(Sathiakumar et al., 2011).
MATERIALS AND METHODS
The ﬁve-step method outlined by Adami et al. (2011) was followed
including (1) collection of all relevant studies, (2) assessment of quality, (3)
evaluation of the weight of evidence, (4) assignment of a scalable conclusion,
and (5) placement on a causal relationship grid. All relevant toxicological and
epidemiological studies were identiﬁed and study quality was assessed
according to guidelines for evaluating toxicological (USEPA, 1993, 2001,
2003a) and epidemiology studies (London Principles, 1995: von Elm, 2007).
Studies that characterize the effect of atrazine on the latency and the incidence
of adenocarcinoma and ﬁbroadenoma in the mammary glands of female
Sprague-Dawley (SD) rats were summarized (Cooper et al., 2007; Eldridge and
Wetzel, 2008; Stevens et al., 1994, 1999).
Studies relevant to the proposed mode of action underlying the effect of
atrazine on mammary tumors were evaluated and a concordance analysis was
conducted. The framework analysis also examined and rejected alternative
modes of action including hypotheses relating to
  Genotoxicity (Brusick, 1994);
  Direct estrogenicity (Eldridge et al., 2008);
  Induction of aromatase expression in vivo resulting in excess formation of
estrogen (Sanderson et al., 2000, 2001; Yi, Simpkins, and Breckenridge,
in preparation); and
  Delayed mammary gland development leading to an extended period in
which the mammary gland remains undifferentiated and vulnerable to
genotoxic or viral carcinogens (Hovey et al., 2010; Russo et al., 2006).
Once the weight of the evidence assessment was completed, the relevance of
the mode of action to humans was considered. This analysis included
a consideration of the dose at which humans are likely to be exposed to
atrazine. The most probable mode of action underlying the occurrence of
mammary tumors in animal models was identiﬁed and whether it was plausible
that the mode of action underlying the mammary tumor response in rats would
be operative in humans.
Epidemiological studies that evaluated the association between human
exposure to atrazine and the incidence of breast cancer were identiﬁed. The
quality of the studies was characterized and whether collectively the results
supported an inference of causality. The overall assessment was completed by
using a causal inference grid and assigning atrazine to one of the four categories
described by Adami et al. (2011).
RESULTS AND DISCUSSION
Effects of Atrazine on Mammary Tumors in Female SD Rats
Stevens et al. (1999) summarized the results from nine
carcinogenicity studies on atrazine in male and/or female SD
rats (ﬁve studies), female Fischer 344 rats (two studies), and
CD-1 mice (two studies). Additional non-guideline studies
were conducted in SD and Fischer-344 rats and in two cross-
bred mouse strains (C57Bl6 x C3H/Anf or AKR) (Table 1). In
female SD rats, atrazine caused a decreased latency and/or
increased combined incidence of mammary adenocarcinoma
and ﬁbroadenoma tumors (Figs. 1a and 1b) with no effect on
the incidence of any other tumor type. There were no effects of
atrazine at the maximum tolerated dose on the incidence
of mammary tumors, on the incidence of any other tumor
type in the female Fischer-344 rats (Fig. 1c) or on tumor
incidence in three strains of mice (Table 1). Overall, the weight
of the evidence indicates that the effect of atrazine on tumor
incidence is speciﬁc to mammary tumors in female SD rats.
Key Events Underlying the Occurrence of Mammary Tumors
in Female SD Rats
Key events (Fig. 2) leading to a decreased latency and an
increased incidence of mammary tumors in atrazine-treated female
SD rats have been proposed (Stevens et al.,1 9 9 4 )s u c ht h a t :
  Atrazine causes a dose-dependent effect on the
synchronized activity of gonadotrophin-releasing hor-
mone (GnRH) neurons during the estrogen-induced
luteinizing hormone (LH) surge so that the amplitude of
the LH surge is reduced (Foradori et al., 2009b).
  The reduction in the LH surge amplitude and a reduced
area under the LH curve causes a failure of the maturing
ovarian follicles to ovulate their eggs.
  The failure of ovulation results in continuous secretion
of estrogen over successive days until the unovulated
follicles undergo atresia.
  Repeated failure of ovulation over successive days of the
estrous cycle produces a persistent state of estrus resulting
in prolonged exposure of the mammary gland and the
pituitary to endogenous estrogen. Estrogen is known to
be mitogenic and a metabolite of estradiol, 4-hydroxy
estradiol, is possibly directly carcinogenic by redox
recycling between a semiquinone and quinine form
liberating supraoxide radicals (Jefcoate et al., 2000).
  Under the inﬂuence of estrogen, proliferative changes
are observed earlier in the mammary gland and in the
442 SIMPKINS ET AL.pituitary. Prolonged stimulation of ductal tissue in the
m a m m a r yg l a n db ye s t r o g e nc a u s e sa ni n c r e a s e d
incidence and a decreased latency of adenocarcinomas
(Sielken et al., 2005).
  Proliferative changes in the pituitary in response to
increased exposure to endogenous estrogens are
postulated to result in an earlier development of
pituitary tumors resulting in hyperprolactinemia
(O’Connor et al., 2000).
  Prolonged exposure of ductal tissue in the mammary
gland to endogenous prolactin is postulated to cause an
earlier occurrence of mammary ﬁbroadenoma (Eldridge
et al., 1999a,b; Eldridge and Wetzel, 2008; Sielken
et al., 2005; Stevens et al., 1994).
Experimental Evidence Supporting the Proposed Mode of Action
Figure 3 shows the number of estrous days in female control
SD rats (Fig. 3a) and in those exposed to 400 ppm atrazine
(Fig. 3b) after 26 weeks of treatment. High-dose atrazine-
treated female SD rats displayed an increased proportion of
days in constant estrus commencing after three months of
treatment (week 13–14) in the 400 ppm dose group (Fig. 3b)
compared with untreated controls (Fig. 3a). A dose-dependent
relationship existed, with a modest increase in the percent days
in estrus noted in the 70 ppm group after nine months of
treatment (Fig. 4b); no effect was observed at feeding levels
less than or equal to 50 ppm (Fig. 4a). The earliest appearance
of disrupted estrous cycles in the 400 ppm treated groups
occurred prior to the earliest appearance of the increased
incidence of mammary tumors (week 26; Fig. 1b). There was
no effect of 400 ppm atrazine on either mammary tumor
incidence (Fig. 1c) or on the estrous cycle in female Fischer-
344 rats (Fig. 4c).
Studies investigating the effect of atrazine on the estrogen-
inducedLHsurgeinfemaleSDandFischer-344ratsindicatethat
doses of atrazine that disrupted the estrous cycle and caused
a decreased latency and/or increased incidence of mammary
TABLE 1
Effect of Oral Administration of Atrazine on the Incidence and/or Latency of Tumors in Rodents
Study reference Species Strain Sex
Levels tested
(mg/kg/day)
Duration
(months) Results
Innes et al. (1969)
(NTP Study)
Mouse C57BL/6 X C3H/Anf;
C57BL/6 X AKR
M and F 21.5
a 18 Negative
Stevens et al. (1999) (M1) Mouse CD-1 M and F 0, 10, 300, and 1000
b M 21, F 22 Negative
Stevens et al. (1999) (M2) Mouse CD-1 M and F 0, 1.6, 47.9, 246.9, and 482.7 21 Negative
Pinte ´r et al. (1990) Rat Fischer-344 M and F 0, 375, and 750
b 29 Inconclusive
Thakur et al. (1998) Rat Fischer-344 F 0, 0.7, 4.7, 13.6, and 27.4 24 Negative
Thakur et al. (1998) Rat Fischer-344 M and F 0, 0.7, 4.7, 13.6, and 27.4 24 Negative
Stevens et al. (1994)
(Study 1)
Rat SD M and F 0, 0.5, 5.5, and 60 24 Male: negative
Female: positive
(0.5, 60 mg/kg/day)
Increased incidence
Stevens et al. (1999) (SDR1) Rat SD M and F 0, 0.5, 3.5, 29.5, and 64.7 24 Male: negative; Female:
positive (3.5, 29.5, 64.7
mg/kg/day)
(Increased incidence)
Stevens et al. (1994)
(Study 3)
Rat SD F 0, 0.7, 3.5, and 37.6 24 Negative
Stevens et al. (1999) (SDR2) Rat SD F 0, 4.3, and 25.6 24 Positive: (early onset)
at 25.6 mg/kg/day
No effect on incidence
Stevens et al. (1999) (SDR3) Rat SD F 0, 4.3, and 25.6 24 Positive: (early onset)
at 25.6 mg/kg/day
No effect on incidence
Stevens et al. (1999) (SDR5) Rat SD F (intact) 0, 1.5, 3.1, 4.2, and 24.4 12, 24 Positive: (early onset)
at 24.4 mg/kg/day
No effect on incidence
Stevens et al. (1999) (SDR4) Rat SD F (ovex) 0, 1.2, 2.5, 3.5, and 20.9 12, 24 Negative
Pettersen and Turnier (1995)
c Rat SD F 0, 0.8, 1.7, 2.8, 4.1, and 23.9 12 Positive: (early onset)
at 23.9 mg/kg/day
No effect on incidence
aOnly female doses given.
bPresented in ppm only, as conversion data were unavailable.
cStudy has not been published.
ATRAZINE, BREAST CANCER, MODE OF ACTION, EPIDEMIOLOGY 443tumors in female SD rats also suppressed the LH surge (Fig. 5a).
In contrast, there was no effect of dietary concentrations of
atrazine up to 400 ppm on the estrogen-induced LH surge in
femaleFischer-344rats(Fig.5b).Thislatterﬁndingisconsistent
with the absence of an effect of atrazine on the estrous cycle
(Fig. 4c) or on the latency or incidence of mammary tumors in
female Fischer-344 rats (Fig. 1c).
The weight of evidence indicates that atrazine induces
mammary tumors in female SD rats by suppressing the LH
surge, thereby supporting a state of persistent estrous and
prolonged exposure to endogenous estrogen and prolactin. The
results are consistent, within and across studies as discussed
above, with respect to dose and duration of exposure needed to
produce the neuroendocrine-mediated effects. The results are
highly speciﬁc to the female SD rat because another strain of
rat, the Fischer-344, is insensitive to this mode of action.
Neither the LH surge, the estrous cycle, nor mammary tumor
incidence are altered in atrazine-treated female Fischer-344 rats
compared with untreated controls. The Fischer-344 rat is non-
responsive because it maintains a normal estrous cycle through
a greater portion of its life span, followed by a decline in
ovarian estrogens similar to the human female (Table 2).
Structure-activity assessments indicate that the chlorotria-
zines share this common mechanism of action. When other
functional groups are substituted for the chlorine atom on the
triazine nucleus (S-methyl, O-methyl, and hydroxy), there was
no effect of treatment on mammary tumor incidence in chronic
bioassays in SD rats (Supplementary Figure S1). Terbumeton,
which has an O-methyl group substitution, was the only
exception (Stevens et al., 1994).
Relevance of the Proposed Mode of Action for Women
Folliculogenesis during the mammalian ovarian cycle is
regulated by relatively low levels of circulating LH and
follicule-stimulating hormone (FSH) produced by a ‘‘basal’’
mode of gonadotropin secretion, which is controlled by the
negative feedback action of ovarian steroids, primarily
estradiol. Ovulation, which occurs at the end of the follicular
phase, is achieved by a massive discharge of LH that is
generated by a ‘‘surge’’ mode of gonadotropin secretion. Both
modes of gonadotropin secretion are dependent on hypophy-
siotropic stimulation from the hypothalamus in the form of
GnRH. Basal gonadotropin secretion is dependent on the
intermittent release of brief ‘‘pulses’’ of GnRH from the
hypothalamus into the hypophysial portal circulation, and this
pulsatile secretion occurs approximately every 20–60 min
depending on species (Freeman, 2006; Zeleznik and Pohl,
2006). The neural mechanism that generates pulsatile GnRH
release is resident in the medial-basal hypothalamus (MBH)
(Blake and Sawyer, 1974; Krey et al., 1975) and is termed the
GnRH pulse generator (Knobil, 1980). While incompletely
understood, emerging models of GnRH pulse generation
suggest similarity across species (Lehman et al., 2010;
Wakabayashi et al., 2010). Intermittent GnRH stimulation of
the gonadotropin-secreting cells of the pituitary, which is
FIG. 1. (a) Atrazine administered at dietary concentrations of 500 or 1000 ppm caused a decreased latency of the combined incidence of adenocarcinoma and
ﬁbroadenoma mammary tumors in female SD rats. The 500 ppm had no effect on the terminal incidence of mammary tumors; 70 ppm was the no observed effect
level (NOEL) for both latency and incidence (Study SDR1, Stevens et al., 1999). (b) Atrazine administered at dietary concentration of 400 ppm caused a decreased
latency of the combined incidence of adenocarinoma and ﬁbroadenoma mammary tumors in female SD. The NOEL was 70 ppm (Studies SDR3; Stevens et al.,
1999). (c) Atrazine administered at dietary concentration of 70 or 400 ppm had no effect on the latency or the combined incidence of adenocarinoma and
ﬁbroadenoma mammary tumors in female Fischer-344 rats (Study FR4; Stevens et al., 1999).
FIG. 2. Key events associated with the earlier appearance and increased
incidence of mammary tumors in atrazine-treated female SD rats.
444 SIMPKINS ET AL.obligatory for sustained gonadotropin secretion (Belchetz
et al., 1978), induces a corresponding pulsatile pattern of LH
secretion into the systemic circulation. Thus, the pulsatile
pattern of LH concentration in peripheral blood serves as
a surrogate for the GnRH pulse generator (Plant, 1986). Surge
gonadotropin secretion is achieved either by ampliﬁcation of
pituitary gonadotropin responsiveness to GnRH pulses or by
activation of a hypothalamic GnRH surge generator that results
in a large and relatively sustained discharge of GnRH into the
hypophysial portal circulation. The relative importance of these
mechanisms for generating gonadotropin surges in mammals is
species dependent.
The estrous cycle in rodents is short, and the pre-ovulatory
LH surge is brief, governed by the light-dark cycle, with the
hypothalamus playing a key role in timing the pre-ovulatory
LH surge (Freeman, 2006). Every afternoon during a critical
FIG. 3. (a) Characterization of the estrous cycle in individual control female SD rats (Study SDR3 Stevens et al., 1999) during treatment weeks 1 and 2, 9 and
10, 13 and 14, 17 and 18, 21 and 22, and weeks 25 and 26. A normal estrous cycle was deﬁned as a cycle lasting four or ﬁve days. Persistent diestrus was deﬁned
as occurring when there were more than two successive days of diestrus; persistent estrus was deﬁned as occurring when there were two or more successive days
when the vaginal smear indicated that the rat was in estrus. Each row represents the result from 1 of 90 rats evaluated in each group. (b) Characterization of the
estrous cycle in individual 400 ppm atrazine-treated female SD rats (Study SDR3, Stevens et al., 1999).
FIG. 4. (a) Dose- and time-dependent effect of 0, 25, 50, or 400 ppm atrazine administered in the diet on the percent days in estrus in female SD rat; 50 ppm
was the no observed effect level (Study SDR3, Stevens et al., 1999). (b) Comparison of the dose- and the time-dependent effects of atrazine administered at dietary
concentrations of 0, 70, or 400 ppm on the percent days in estrus in female SD rats; 70 ppm was the no observed effect level (Study SDR3, Stevens et al., 1999). (c)
Atrazine administered at dietary concentrations of 70 or 400 ppm had no effect on the percent days in estrus in female Fischer 344 rats (Study FR2, Stevens et al.,
1999).
ATRAZINE, BREAST CANCER, MODE OF ACTION, EPIDEMIOLOGY 445period spanning ~2 h, the rodent brain generates a circadian
signal, which in combination with the positive feedback action
exerted by the elevated levels of circulating estradiol on
proestrus, activates the GnRH surge generator that triggers
the LH surge. Thus, the role of the rodent brain in controlling
the timing of ovulation may be viewed as deterministic. The
hypothalamic neurons synthesizing GnRH in the rodent brain
are located primarily in the pre-optic area (POA), with few in
the more caudal MBH (Silverman et al., 1994). Release of
GnRH into the portal circulation is dependent on increased
activity of norepinephrine neurons located in the brainstem
(Sawyer, 1995; Simpkins et al., 1979a,b; Herbison, 1997; Wise
et al., 1997, 1999) and on kisspeptin neurons located in the
anteroventral periventricular nucleus of the POA (Oakley et al.,
2009), the site of positive feedback of ovarian estradiol
(Goodman, 1978). As such, inhibition of neural activity early
in the afternoon of proestrus by administration of barbiturate or
other centrally-acting drugs blocks the pre-ovulatory LH surge
in rats (Freeman, 2006, Goodman and Knobil, 1981). Another
fundamental characteristic of the GnRH surge mechanism in
the rodent is its susceptibility to perinatal programming by
testicular androgens such that the hypothalamus of the adult
male rat is unable to respond to the positive feedback of
estradiol (Feder, 1981).
The human menstrual cycle is long and exhibits a protracted
pre-ovulatory LH surge spanning 2–3 days and ends with
menses, due to the involution of the corpus luteum and the
resulting decline in estrogens and progesterone (Hall, 2009;
Zeleznik and Pohl, 2006). In contrast to the rodent, the role of
the primate brain, although obligatory in driving the menstrual
cycle, is permissive rather than deterministic. In the human
female, the preovulatory LH surge appears to occur in the
FIG. 5. (a) Atrazine administered for 6 months at dietary concentration of 400 ppm signiﬁcantly suppressed the estrogen-induced LH surge in female SD rats;
50 ppm was the no observed effect level (Study SDR3, Stevens et al., 1999). (b) Atrazine administered for 6 months at a dietary concentration of 400 ppm had no
effect on the estrogen-induced LH surge in female Fischer-344 rats (Study FR2, Stevens et al., 1999).
TABLE 2
Species Differences in Reproductive Senescence (Adapted from Chapin et al., 1996)
Parameter SD rat Fischer-344 rat Women
Start of Senescence
(% of normal lifespan)
30–40% 60–70% 60–70%
Principal cause of senescence Hypothalmic failure to
stimulate LH/FSH
Hypothalmic failure to
control prolactin surges
Depletion of ovarian
follicle content
LH surge capability Lost Maintained Maintained
Predominant cycle pattern Persistent estrus Pseudopregnancy episodes Menopause
Estrogen/progesterone ratio Elevated/prolonged Reduced Reduced
Prolactin secretion Persistently elevated Episodically elevated Reduced
Spontaneous mammary
tumor incidence (lifetime)
30–40% 2–5% 8–10%
Principal known factors
that increase MT Risk
Prolactin, estrogen,
chemical mutagens
Prolactin, estrogen,
chemical mutagens
Estrogen, nulliparity,
family history
Prolactin dependence High Medium None
446 SIMPKINS ET AL.absence of a GnRH surge (Hall et al., 1994; Martin et al., 1998;
Ottowitz et al., 2008) and unfolds in the face of an unchanging
frequency of the GnRH pulse generator, as reﬂected by
pulsatile LH release (Adams et al., 1994; Martin et al., 1998).
Thus, it must be concluded that the LH surge is timed and
elicited by a positive feedback action of estradiol at the level of
the pituitary to dramatically enhance responsiveness to
pulsatile GnRH stimulation in women. Indeed, the spontaneous
menstrual cycle can be recapitulated in women deﬁcient in
GnRH, simply by the exogenous administration of a series of
pulses of GnRH (Hall, 2009; Filicori et al., 1986; Martin et al.,
1998; Santoro et al., 1986). These ﬁndings indicate that the
entire pattern of gonadotropin secretion throughout the human
menstrual cycle is governed by the negative and positive
feedback actions of ovarian estradiol at the level of the
pituitary. Similar observations regarding pulsatile GnRH
replacement have been made in female rhesus monkey
following hypothalamic lesions that abolish endogenous GnRH
release (Knobil et al., 1980; Zeleznik and Pohl, 2006). In the
monkey, however, the preovulatory LH surge is associated
with a GnRH surge (Pau et al., 1993), which, in contrast to the
rat, the GnRH surge is timed solely by the positive feedback
action of estradiol acting at the level of the MBH-pituitary unit
(Karsch et al., 1973). Unlike the rodent, many GnRH neurons
in primates are located in the MBH (Silverman et al., 1994).
In contrast to rodents (Simpkins et al., 1985), inhibition of
neural activity by administration of barbiturates or other
centrally acting drugs does not affect the estrogen induced
pre-ovulatory LH surge in women or the female monkey
(Knobil, 1974; Weiss et al., 1977). The hypothalamic control
of the pre-ovulatory LH surge in primates is emancipated from
perinatal programming by testicular androgen secretion, as
reﬂected by the ability of estradiol to elicit LH surges in adult
male rhesus monkeys castrated postpubertally, and either
bearing a subcutaneous ovarian transplant (Norman and Spies,
1986) or receiving estradiol to mimic a late follicular phase
pattern of circulating estradiol (Karsch et al., 1973).
Reproductive aging in rodents and women is also different.
In female SD rats, reproductive senescence occurs as a result of
a breakdown of the brain regulation of the LH surge, while the
ovaries remain functional very late into life (Aschheim, 1976;
Meites et al., 1978). The decline in reproductive function is
primarily a result of (1) the inability of brain norepinephrine
neurons to transmit the estrogen signal to GnRH neurons
(Meites et al., 1978; Simpkins et al., 1979a,b; Weiss et al.,
1977), (2) the inability to stimulate a pre-ovulatory LH surge
resulting in the maintenance of ovarian follicles, and (3) the
persistent secretion of estrogens. Increased secretion of estro-
gens causes a persistent state of hyperprolactinemia (Sarkar
et al., 1982). Thus in the SD rat, reproductive senescence is
characterized by persistent hyperestrogenemia and hyper-
prolactinemia with low levels of LH and FSH.
In contrast to female SD rats, which begin to display
episodes of persistent estrus as early as six months of age,
female Fischer-344 rats maintain normal 4–5 day estrous
cycles through 18 months of age (Estes et al., 1982; Estes and
Simpkins, 1984; Lu et al., 1979, 1980). At two years of age,
Fischer-344 rats display normal estrous cycles, interspersed
with periods where corpus lutea (CLs) are maintained for
extended periods, accompanied by secretion of ovarian pro-
gesterone (Estes and Simpkins, 1984; Lu et al., 1980). Thus, in
the aging Fischer-344 rat, the hypothalamic-pituitary-gonadal
(HPG) axis maintains the ability to mediate an estrogen-induced
LH surge although it cannot inhibit episodic prolactin surges
after the LH surge has occurred (Estes and Simpkins, 1982).
This creates an endocrine state called pseudopregnancy (Beach
et al.,1 9 7 5 ; Estes et al.,1 9 8 2 ) because prolactin secretion is
prolonged and CLs are maintained (Estes et al.,1 9 8 2 ).
In women, reproductive aging and the occurrence of
menopause is due to the exhaustion of ovarian follicles and
a diminution of ovarian estrogen (Burger et al., 2007; Hale and
Burger, 2005; Hale and Burger, 2009; Rance, 2009; Schiff and
Wilson, 1978). During the menopause, however, the ability of
exogenous estrogens to induce a pre-ovulatory LH surge is
maintained, albeit slightly diminished (Santoro, 2005). In the
absence of endogenous estrogen secretion, the feedback signal
from the ovary governing the cyclic pattern of gonadotropin
secretion is lost, and a constant hypergonadotropic state is
produced as a result of GnRH pulse generator activity that is
robustly maintained in the postmenopausal women. Post-
menopausal estrogens and prolactin are very low, but LH and
FSH secretions are greatly elevated (Burger et al., 2007; Hale
and Burger, 2005; Hale and Burger, 2009; Rance, 2009; Schiff
and Wilson, 1978). The major differences between aging of the
human menstrual cycle and rodent estrous cycles are
summarized in Table 2 and discussed speciﬁcally for atrazine
in Chapin et al. (1996).
Possible Alternative Modes of Actions
Genotoxicity. Atrazine is one of the most extensively
tested chemicals for genotoxicity. Published studies include
in vitro and in vivo experiments with mammalian cells,
microbial systems, invertebrates, ﬁsh, and several plant species
(Supplementary Tables S1 and S2; Brusick, 1994). Utilizing
a weight of the evidence approach developed by the
International Commission for Protection against Environmental
Mutagens and Carcinogens (Brusick et al., 1992; Lohman
et al., 1992), Brusick (1994) evaluated all published and
registrant studies on the genotoxicity of atrazine. The
evaluation was later expanded to include all studies published
through December 2010. Seventeen of the 23 gene mutation
studies following in vitro exposure of mammalian cell lines to
atrazine were negative (Supplementary Table S1); gene
mutation studies on atrazine metabolites (hydroxyatrazine,
deethyl atrazine [DEA], deisopropylatrazine [DIA], and
diaminochlorotriazine [DACT]) were also negative (Supple-
mentary Table S3). With the exception of studies conducted in
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the studies show that atrazine or its metabolites do not directly
interact with DNA resulting in mutation. Hence, governmental
agencies responsible for reviewing and interpreting toxicology
data have concluded that atrazine is not genotoxic (APVMA,
2004, 2008; FAO/WHO, 2009; International Agency for
Research on Cancer (IARC), 1999; USEPA, 2003a).
While the results shown in Supplementary Tables S1–S3 are
predominately negative, there are a few isolated positive
results. Isolated conﬂicting responses are not uncommon when
a chemical is evaluated in a large number of studies. Such
isolated occurrences are considered spurious responses due to
normal variability or technical inadequacies (Brusick et al.,
1998). Multiple positive responses tended to occur for those
methods that detect chromosomal damage (structural or
numerical changes) or DNA strand breakage (Gebel et al.,
1997; Pino et al., 1988; Ribas et al., 1995; Singh et al., 2008).
Unlike tests measuring gene mutation, these types of studies
can give positive responses due to cytotoxic or other secondary
effects that are not true indicators of a genotoxic mode of
action. Atrazine has been reported to cause lipid peroxidation
in vivo at high doses (Singh et al., 2011), and oxidative
peroxidation is known to cause cell death and necrosis, which
will yield false-positive effects in tests such as alkaline elution
techniques and the comet assay (Choucroun et al., 2001; Pool-
Zobel et al., 1999). A study by Singh et al. (2008) reported
increased micronuclei and comet tail lengths in liver cells
obtained from rats exposed to 300 mg/kg of atrazine for 7, 14,
and 21 days. This dose level appeared to be high enough to
induce oxidative damage in the target tissue, as the reported
positive effects were minimized by the co-administration of an
antioxidant. Consequently, the increased levels of DNA strand
breakage in this and other elution assays may have been
secondary to toxicity-induced apoptosis and not from direct
effects of atrazine on liver cell DNA.
Some studies report chromosomal changes in atrazine-
exposed cells evaluated using ﬂow-cytometry (Biradar and
Rayburn, 1995a,b; Rayburn et al., 2001; Taets et al., 1998).
Flow cytometry quantiﬁes changes in whole-cell DNA or
individual chromosomes through analysis of coefﬁcients of
variation (CVs) in ﬂow histograms. Biradar and Rayburn
reported that atrazine caused a statistically signiﬁcant increase
in the CV of DNA content of G1 cells at concentrations as low
as 0.005lM. In an assessment of the Biradar and Rayburn
ﬂow studies, Kligerman et al. (2000a) concluded that ﬂow
cytometry and the use of changes in CV is not a reliable
method for the determination of clastogenicity. Application of
ﬂow analysis to chromosomal CV is generally subjected to
computer-generated analysis of the results. Biradar and
Rayburn (1995a) were unable to ﬁnd statistically signiﬁcant
increases in the atrazine results using computer-based analysis
and instead applied a unique manual approach to their studies
to generate positive effects. When utilizing methods that permit
the direct visualization of chromosomal damage, the vast
majority of atrazine studies were negative (Adler, 1980; Basler
and Rohrborn, 1978; Meisner et al., 1992; Kligerman et al.,
2000a,b; Ribas et al., 1998).
Supplementary Table S4 gives the results of genotoxicity
studies in plants and fungi. Atrazine is active in most plant-
based tests as well as in a number of tests employing fungi.
Compared with the data from tests in animals or animal cells,
these results indicate that atrazine is handled differently in
plant-based systems. Although there may be multiple reasons
for the differences, clearly unique attributes of animal
metabolism and detoxiﬁcation processes not present in plant-
based systems are likely most relevant. Thus, these studies are
of minimal value in evaluating the genotoxicity potential of
atrazine.
Except for studies on genotoxicity in plants and fungi, there
is no reason to give more weight to in vivo studies versus
in vitro studies because the chloro- and hydroxyl- metabolites
of atrazine tested for mutagenic potential in in vitro are the
predominant metabolites formed in vivo (Kim et al., 2010;
McMullin et al., 2003). Oxidative metabolism of atrazine
(Supplementary Figure S1) has been well characterized in vitro
and in vivo in rodents (Hanoika et al., 1999), nonhuman
primates (Hui et al., 2011; Maibach et al., 2001) and humans
(Ademola et al., 1993; Buchholtz et al., 1999; Joo et al., 2010;
Maibach et al., 2001). Although phase II metabolites such as
glutathione conjugates and mercapturates (Supplementary
Figure S2) are unique to in vivo systems and their formation
in vivo might be a basis for assigning more weight to in vivo
studies, these metabolites appear to be toxicologically less
active (USEPA, 2002; Yi, Simpkins, and Breckenridge, in
preparation) and are rapidly eliminated (Hui et al., 2011;
Maibach et al., 2001). Overall, considering the results from
both in vitro and in vivo models, the weight-of-evidence
supports the conclusion that atrazine and its phase I and phase
II metabolites are unlikely to be genotoxic.
Estrogen receptor agonist/antagonist. Eldridge et al.
(2008) recently summarized the results of more than 40 studies
that evaluated the potential of atrazine to bind to or interact
with estrogen receptors (ERs) in 17 estrogen-dependent
systems in vivo or in more than a dozen different ER reporter
or binding systems in vitro. None of the 24 studies that
evaluated the in vivo expression of estrogen following atrazine
exposure showed any estrogen-agonist effects, irrespective of
the species or the strain of rat evaluated (Supplementary Table
S5). In 10 of 15 studies, atrazine inhibited the action
of estrogen in vivo, but only when the administered dose
of atrazine was at least 100,000 times greater than the dose of
estradiol. Four other studies showed no effect of atrazine at
high concentrations and one study was inconclusive. None of
the 18 studies reported any stimulatory effect of atrazine on
estrogenic expression systems in vitro; weak inhibition of
estrogen was reported in 3 of 10 studies (Supplementary Table
S6). Weak competition between atrazine and estrogen for ERa
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from a variety of species including two strains of rats
(Supplementary Table S7). In some studies, weak competition
was seen only when atrazine was pre-incubated with the
receptor before estradiol was added to the media.
Overall, the weight of evidence indicates that atrazine does
not act as an estrogen agonist. Atrazine may act as a weak ER
antagonist if present in tissues at concentrations that are more
than 100,000-fold greater than the concentration of estradiol.
This is unlikely to occur under conditions of human exposure.
For example, a 60 kg person consuming 2 l of water containing
atrazine at the Maximum Contaminant Level (MCL) of 3 ppb
would receive a dose of 0.1 lg atrazine/kg. Assuming the
human plasma concentration scaled 1:1 to the plasma
concentration determined in the rat (See Supplementary Figs.
S4 and S5), then the expected steady state plasma concentra-
tion of total triazine in humans exposed at the MCL would be
0.1 ppb (4.8 3 10
 10M). Total chlorotriazine concentration in
plasma is expected to be approximately ﬁvefold lower in
humans because the concentration of total chlorotriazine
eliminated in urine of men comprised only 14.4% of the
administered dose (Maibach et al., 2001). Tissue concentration
of atrazine is likely to be at parity with plasma at steady state
because plasma:tissue partition coefﬁcients are near 1.0 (P. S.
Coder, unpublished data). The Kd for estradiol binding to the
estrogen receptor is 7.7 3 10
 10M( Laws et al., 2006; Rider
et al., 2009). Thus, under conditions of human exposure, the
concentration of atrazine equivalents in tissue is approximately
the same as the Kd for estradiol. Therefore, it is unlikely that
atrazine will antagonize the binding of estradiol to its receptor
in vivo. Even if atrazine was a weak estrogen receptor
antagonist in vivo, the consequence would likely be a diminu-
tion of estrogenic activity rather than an increase called for by
the results of the carcinogenicity studies on atrazine.
Induction of messenger RNA for aromatase and/or aroma-
tase enzyme activity. In vitro studies (Sanderson et al., 2000,
2001) indicate that high concentrations of atrazine in 0.1%
dimethyl sulfoxide increases aromatase activity and gene
expression in the H295R adrenocorticocarcinoma cell line
and in JEG-3 placental choriocarcinoma cells but not in the
MCF-7 breast cancer cells or the R2C rat Leydig cell cancer
cells (Heneweer et al., 2004; Supplementary Table S8). Carp
hepatocytes treated with atrazine in vitro did not show altered
vitellogenin synthesis (Sanderson et al., 2001). In the majority
of these studies, statistically signiﬁcant induction of aromatase
activity or gene expression was observed only at the
concentration near the solubility limit of atrazine (30lM; 6.5
ppm) although effects on aromatase have been reported in
some studies at 10lM but not at 1lM of atrazine (Yi, Kim,
Breckenridge, and Simpkins, in preparation). Ohno et al.
(2004) reported that aromatase activity was unaffected by
atrazine in KGN ovarian granulosa carcinoma cells and Keller
and McClellan-Green (2004) found no effect of atrazine in an
immortalized sea turtle cell line. The results from primary
ovarian granulosa and endometrial stromal cells are mixed.
Tinfo et al. (2011) reported a 2- to 2.5-fold increase in
aromatase activity with atrazine but no change in aromatase
message or protein in rat granulosa cells. Holloway et al.
(2008) did not see a dose-response in human granulosa cells
exposed ex vivo to atrazine and found no effect of atrazine on
human endometrial stromal cells (Supplementary Table S8).
Crain et al. (1997) and Spiteri et al. (1999) reported increased
aromatase activityinalligator eggspainted with14ppmatrazine
dissolved in ethanol. Even under these extreme conditions, not
a single male was converted to a female. In contrast, when the
male eggs were treated with 14 ppb of estradiol, 100% of the
males were feminized. This indicates that the reported changes
inaromataseinalligatoreggswereofnofunctionalconsequence.
A study in chicken eggs failed to show any effect on atrazine on
aromatase activity (Matsushita et al.,2 0 0 6 ).
The effect of other chlorotriazines such as simazine, as well as
primary (Supplementary Figure S1) and secondary metabolites of
atrazine (Supplementary Figure S2) on aromatase activity has
been investigated (Supplementary Table S8). Exposure to DEA
and DIA resulted in weaker responses than did exposure to
atrazine, whereas DACT, the major animal chlorometabolite of
atrazine, had no effect (Sanderson et al.,2 0 0 0 ; Tinfo et al., 2011;
Yi, Kim, Breckenridge, and Simpkins, in preparation). The
glutathione and mercapturate conjugates of atrazine, which are
secondary metabolites of atrazine, as well as hydroxyatrazine
(HA) and ammeline, which are major plant metabolites, had no
effect on aromatase messenger RNA (mRNA) in H295R or JEG3
cells (Yi, Kim, Breckenridge, and Simpkins, in preparation).
The weight of the evidence indicates that high micromolar
concentrations of atrazine and to a lesser extent, its mono-
dealkylated metabolites at concentrations above the solubility
limit in aqueous media, cause an approximately twofold
increase in expression or activity of aromatase in sensitive cell
lines capable of steroidogenesis. Neither the major atrazine
chlorometabolite, DACT, nor the glutathione or mecapturates
of atrazine had any effect; HA or ammeline, the predominant
plant metabolites of atrazine also were negative (Yi, Kim,
Breckenridge, and Simpkins, in preparation). Because atrazine
and the mono-dealkylated metabolites of atrazine are rapidly
metabolized after ingestion, these chemicals are not expected to
persist long enough to have any effect on aromatase activity
in vivo (APVMA, 2010; FAO/WHO, 2009; Yi, Simpkins, and
Breckenridge, in preparation). As discussed in the previous
section, tissues concentration of atrazine equivalents will not be
greater than 10
 10M for humans exposed to atrazine at the
MCL. In the rat, a repeated oral dose of 0.25 mg/kg for 5 days
would be needed to produce a tissue concentration of 1lM
atrazine (Supplementary Fig. S5), a concentration which
clearly had no effect on aromatase activity or expression when
evaluated in any in vitro system. However, atrazine is rapidly
metabolized to less active metabolites, most notably DACT
and the concentration of atrazine in plasma is short lived (tmax
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Kim et al., 2010). In contrast, in the in vitro aromatase models,
atrazine had to be present in media for at least 2 h at
a concentration above 1lM to signiﬁcantly affect aromatase
mRNA expression (Yi, Kim, Breckenridge, and Simpkins, in
preparation).
Studies on intact animals (Supplementary Table S9) indicate
that neither the induction of mRNA aromatase gene expression
nor the increased aromatase activity is observed in atrazine-
treated animals. Hayes et al. (2002) argued that changes in
circulating or whole body testosterone reﬂect an alteration in
aromatase activity in atrazine-exposed Xenopus laevis. How-
ever, this cannot be taken as evidence that atrazine is altering
aromatase expression because plasma hormone levels change
dynamically from moment to moment and are subject to a host
of variables (age, sex, season, time of day, and stress level) that
are uncontrolled in environmental studies (Kang et al., 1995).
Other studies have failed to observe a relationship between
triazine exposure and testosterone levels in wild-caught
Xenopus laevis (Hecker et al.,2 0 0 4 ). Furthermore, the reported
‘‘feminization’’ effect of atrazine on amphibian gonadal
development (Hayes et al., 2002), which has been attributed
to an effect on aromatase, has not been replicated by other
laboratories (Kloas et al., 2009a). Lastly, when changes in
aromatase mRNA were evaluated in amphibians, no effects of
atrazine exposure were found (Hecker et al., 2004, 2005a,b;
Kloas et al., 2009b).
High doses of atrazine (50 or 200 mg/kg/day) administered
daily to 60-day-old male Wistar rats for 1, 2, 3, 4, or 21 days
resulted in slight and highly variable increases in serum
androstenedione, testosterone, estradiol, estrone, corticoste-
rone, and progesterone, as quantiﬁed by radio-immuno-assay
(Modic et al., 2004). Although the acute effect of high doses of
atrazine on corticosterone and progesterone have been
conﬁrmed in subsequent studies (Fraites et al., 2009; Laws
et al., 2009), the effect on androstenedione testosterone,
estradiol, and estrone has not been conﬁrmed by liquid
chromatography with tandem-mass spectrometry (LC-MS-
MS) using internal
13C-stable label for identiﬁcation and
unlabeled standards for quantiﬁcation (Handa, 2010).
Overall, the weight of the evidence indicates that high
micromolar concentrations of atrazine and its mono-dealkylated
metabolites, but not DACT, caused an approximate twofold
increase in aromatase mRNA and activity in immortalized cell
cultures in vitro. The absence of effects in vivo is likely
attributed to the rapid metabolism to inactive metabolites (Kim
et al.,2 0 1 0 ). Hence, the in vitro mode of action is not likely
relevant to intact mammals.
Delayed development of the mammary gland. It has been
proposed that a delay in the development and differentiation of
mammary gland increases susceptibility to physical, chemical,
or viral agents that initiate cancer (Russo et al., 1992;
Trichopoulos et al., 2008), whereas factors that delay the
onset of menarche are protective (Russo et al., 2001, 2006).
In utero exposure of female Long-Evans rats to 100 mg/kg/day
atrazine (Rayner et al., 2005) or a mixture of atrazine and its
metabolites (Enoch et al., 2007) has been reported to delay
postnatal mammary gland development using, for the most
part, subjective rating scales. When an unbiased, blinded
quantitative assessment of mammary glands (ductal length,
ductal area, epithelial area, epithelial density, and cell
proliferation) was used, there was no evidence of a delay in
mammary gland development at doses of atrazine up to
100 mg/kg/day (Hovey et al., 2010). Hovey and colleagues
controlled for the effect of treatment-related reductions in body
weight gain in the pregnant dams on subsequent pup
development, as well as for atrazine-induced delay in sexual
maturation, which has been reported in atrazine-treated females
(Ashby et al., 2002; Laws et al., 2000). Delay in sexual
maturation is known to affect mammary gland development
because growth during puberty is allometric and sensitive to
hormonal changes during the estrous cycle (Hovey et al.,
2002). The results from a second laboratory conﬁrmed the
absence of an atrazine effect on postnatal mammary gland
development at doses as high as 100 mg/kg/day (Davis et al.,
2011). In addition, female SD rats exposed to atrazine in utero
and throughout life did not have an increased incidence of
mammary tumors compared with controls, suggesting that
in utero exposure to atrazine did not contribute to an increased
risk of developing mammary tumors later in life (Stevens et al.,
1999). However, this study was underpowered (N ¼ 30 per
group); thus small effects may not have been detectable.
Overall, there is no compelling evidence to indicate that
in utero exposure to atrazine increases the incidence of
mammary tumors in rodents. There is a clear trend among
females in developed countries to experience an earlier onset of
puberty, leading to an earlier rather than a delayed development
of breasts in young girls. The prolongation of exposure to
endogenous estrogen increases breast cancer risk later in life
(Russo et al.,2 0 0 6 ; Trichopoulos et al., 2008).
Conclusions of Animal Mode of Action Research
Thehypothesisthatdecreasedlatencyandincreasedincidence
of mammary tumors in female SD rats is mediated through the
key events shown in Figure 2, is strongly supported by the data.
This conclusion is consistent with a detailed analysis conducted
by FAO/WHO (2009; Appendix 1, pp 118–124).
The mechanism of action underlying the effect of atrazine on
the HPG axis is unknown because the molecular target(s) have
yet to be identiﬁed. Some hypotheses have been ruled out but
none has been established (Cooper et al., 2007). Recent work
has allowed for a comparison of the effect of atrazine on the
HPG and HPA axes in female Wistar, Long-Evans, and SD
rats. Although the Wistar and inbred strains of Long-Evans rats
have not been evaluated in traditional carcinogenicity studies,
both SD and Long-Evans rats were derived from the original
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Evans rats respond to high doses of atrazine with reduced LH
surges (Cooper et al., 2000; Foradori et al., 2009a,b). New
mechanistic studies suggest that the effect of atrazine on the
LH surge may be secondary to an activation of corticosterone
release in the rat (Fraites et al., 2009; Laws et al., 2009).
However, the effect of atrazine on the estrogen plus pro-
gesterone induced LH surge in female Wistar rats was
unaffected by adrenalectomy, whereas the suppressive effect
of atrazine on pulsatile LH release was abolished (Foradori
et al., 2011). This suggests that the effect of atrazine on the
ﬁnal common hypothalamic pathway (i.e., suppression of
pulsatile versus surge release of GnRH/LH) may be mediated
via distinct mechanisms in rodents. This dichotomy in the
response to atrazine is intriguing because the control
mechanism of pulsatile GnRH release in nonhuman primate
and women is similar to the rodent control mechanisms. In
contrast, major differences exist in the regulation of the LH
surge in rodents compared with nonhuman primates and
women. In the human female, the preovulatory LH surge
appears to occur in the absence of a GnRH surge (Hall et al.,
1994; Martin et al., 1998; Ottowitz et al., 2008).
The proposed mode of action underlying the decreased
latency and increased incidence of mammary tumor response in
the female SD rat is unlikely to be relevant to women due to the
differences in reproductive aging of rodents and women.
Although it is plausible that high doses of atrazine could
suppress the LH surge in women by interfering with GnRH
pulse generation, the consequence of that suppression would
not result in an increased incidence of breast cancer in women.
Therefore, atrazine was placed in the lower half of the
biological plausibility scale described by Adami et al. (2011).
There is little uncertainty in this conclusion because of the
quality and the breadth of the studies that underlie the
assessment. This conclusion is consistent with independent
reviews by regulatory authorities around the world (AVMPA,
2004, 2008; FAO/WHO, 2009; IARC, 1999; USEPA, 2003b,
2006).
The evidence supporting alternative modes of action
evaluated in this paper (genotoxicity, estrogenicity, aromatase,
and delayed mammary gland development) is not compelling
and do not indicate that these alternate modes of action play
a role in the mammary tumor response observed in atrazine-
treated female SD rats. These alternate modes of action are also
unlikely to contribute to the occurrence of breast cancer in
women, especially at doses to which women could conceivably
be exposed.
Atrazine exposure and breast cancer: epidemiological
evidence. The potential association between atrazine expo-
sure and the risk of breast cancer has been evaluated in
epidemiological studies of incidence or mortality among
women involved in triazine manufacture (MacLennan et al.,
2002, 2003); women who lived on farms (Engel et al., 2005)o r
in proximity to farms and/or were associated with agricultural
work (Reynolds et al., 2004); and women potentially exposed
to atrazine via drinking water (McElroy et al., 2007).
Ecological studies have also been conducted in which breast
cancer incidence was examined across geographic areas
deﬁned by triazine exposure (Hopenhayn-Rich et al., 2002;
Kettles et al., 1997; Mills and Yang, 2006; Muir et al., 2004;
Reynolds et al., 2005).
Cohort studies on women involved with triazine manufac-
ture. Breast cancer incidence was examined in women
employed in the manufacture and formulation of triazines
(primarily atrazine). Among 184 women employed in a Loui-
siana plant who were followed from 1985 to 1997, one was
diagnosed with breast cancer (expected ¼ 1.5) (MacLennan
et al., 2002). In a parallel study of mortality at this same plant,
there was one death from breast cancer during 1970–97 among
211 female employees (expected ¼ 0.6) (MacLennan et al.,
2003).
The quality of these studies was classiﬁed as acceptable. One
strength was that exposure to atrazine at this production facility
could be quantiﬁed using job histories in a fashion similar to
that employed by Hessel et al. (2004) in a study of prostate
cancer at this facility. The major weakness was that there were
only a few breast cancer cases and thus the study did not have
adequate statistical power.
Cohort studies on women with potential exposure to atrazine
or triazines on farms. Spouses of professional pesticide
applicators, recruited to the Agricultural Health Study in Iowa
and North Carolina from 1993 through 1997, provided
information about their own herbicide exposures and potential
risk factors for breast cancer (Engel et al., 2005). Of the 309
women who went on to be diagnosed with breast cancer
through the year 2000, only 11 (3.6%) had directly used
atrazine; this was similar to the percentage for controls
diagnosed with breast cancer (4.4%, relative risk [RR] ¼ 0.7,
95% conﬁdence interval [CI] 0.4–1.2). Among women who did
not apply any pesticide, the percentage of their husbands who
had done so was similar for cases and controls (74.8 vs. 73.8%,
respectively, RR 1.1, 95% CI 0.7–1.6). Similar results were
obtained when the assessment was based on 13 women with
breast cancer who reported using triazines (Supplementary
Table S10).
The study was classiﬁed as acceptable. The strength of the
study was its prospective design with exposure assessment
prior to disease diagnosis. The weakness was that there were
too few cases through the end of 2000 to provide adequate
statistical power.
The California Teachers study evaluated residential proxim-
ity to areas of simazine application and incidence of breast
cancer in these regions (Reynolds et al., 2004). In this study,
1552 participants were diagnosed with breast cancer during
1996 through 1999. Using data obtained in the California
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incidence of breast cancer was examined in relation to the
amount of various pesticides and herbicides applied in the area
within one-half mile of the residence of each participant. Breast
cancer incidence did not vary appreciably across levels of
simazine application compared with women living in an area in
which less than one pound of simazine per square mile had
been applied; the relative incidence was 0.9, 0.9, and 1.1 for
women living in areas of simazine application of 1–13 pounds
per square mile, 14–40 pounds per square mile and 41 or more
pounds per square mile, respectively. A subset analysis of
women who lived within 0.5 mile radius of the section of land
sprayed or who lived within the section of land sprayed,
yielded hazard ratios of 1.17 (CI ¼ 0.82–1.67) and 1.44 (CI ¼
1.01–2.05), respectively, based upon an unspeciﬁed numbers
of cases.
This study was categorized as acceptable. Strengths of the
study included a large number of breast cancer cases and the
control for suspected risk factors for breast cancer. However,
the relationship between residential proximity to application of
simazine and actual exposure was not quantiﬁed. Furthermore,
confounding for co-exposure to other pesticides, which were
used in proximity to the residence of women with breast
cancer, was not controlled.
Case-control study on women with potential exposure to
atrazine via groundwater. This study evaluated the amount of
atrazine in the groundwater near residences of women with and
without breast cancer (McElroy et al., 2007). Female residents
of rural Wisconsin (ages 20 through 79 years) who had been
diagnosed with breast cancer during 1987 through 2000 were
identiﬁed (n ¼ 3275), as were 3669 demographically-similar
control women. All women were interviewed with respect to
exposure and characteristics relevant to the risk of breast
cancer. Using data from surveys of atrazine levels in well water
in 1994, 1996, and 2001, the investigators assigned an atrazine
level to each woman’s own well water, based on the proximity
of the well to those wells for which atrazine concentration had
been determined. The distribution of estimated levels of
atrazine in well water was nearly identical between the wells
of cases and those of the controls. For women whose water was
estimated to contain less than 0.15 ppb of atrazine, the relative
risk of breast cancer in those whose water had 1–3 ppb atrazine
was 1.1 (95% CI 0.9–1.4), adjusted for other breast cancer risk
factors. Only nine women (ﬁve cases and four controls) had
wells with an atrazine concentration estimated at greater than
3 ppb, too small a number to draw any conclusion.
Study quality was classiﬁed as acceptable. Strengths
included the fact that 83 percent (11,001) of eligible case
women and 83.1% (11,494) of eligible age-matched control
FIG. 6. Summary of the weight of evidence of the mode of action
(biological plausibility) and the epidemiological evidence for a causal
relationship between atrazine exposure and the occurrence of breast cancer in
women.
TABLE 3
Framework Assessment of the Animal Mode of Action, the
Relevance of the MOA to Breast Cancer in Women and the
Epidemiology Evidence
EPA human cancer
classiﬁcation Carcinogenic Likely Suggestive
Not
likely
Human evidence
Causation established No
Association established No
Animal evidence
Multi versus single
(sex, species, strain,
and site)
Yes
Mode of action
Key events proposed Yes
Concordance of dose
response relationships
Yes
Temporal association
of key events
Yes
Strength, consistency,
and speciﬁcity of
association
Yes
Biological plausibility
and coherence
Yes
Alternative MOAs
evaluated
Yes
Human relevance
MOA operative at
any dose
No
MOA operative at
plausible human dose
No
Framework: unlikely
(category 4)
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used to assign residence and well water concentration of
atrazine or atrazine plus its chlorometabolites, but there was no
control for duration of time in residence. The authors controlled
for confounding by potential breast cancer risk factors
(Supplementary Table S11). Weaknesses in the study included
the fact that atrazine exposure was not assessed during a period
of time that was etiologically relevant to development of
breast cancer. In general, atrazine concentrations in ground-
water were low (0.15–3 ppb) and varied over too narrow
a concentration range to plausibly permit the documentation of
a dose-response.
Ecological studies on breast cancer and triazines use in
geographical regions. Because ecological studies are gener-
ally hypothesis generating rather than hypothesis testing, the
quality of individual studies in this category are not discussed
except for the study of Muir et al. (2004), which appeared to
have major limitations.
Reynolds et al. (2005) characterized residences in each
square mile of the state of California in terms of estimated
pesticide application during 1990 through 1997. The incidence
of breast cancer during 1988 through 1997 bore no relation to
the quantity of simazine application: rates were identical
among women living in areas in the upper-fourth of the
distribution of simazine application and those living in areas
where virtually no simazine had been applied (RR 1.0, 95% CI
0.95–1.07).
A county-level study in California among Latin women
during 1988 through 2000 similarly found no association
between the incidence of breast cancer and the quantity of
application of either simazine or atrazine (Mills and Yang,
2006). After adjusting for age, socioeconomic status, and
fertility rates, the RRs for low, mid, and high ‘‘exposed’’
groups ranged from 0.83 to 0.87, 0.94 to 0.91, and 0.86 to 0.87,
respectively, for assessment periods from 1988 to 1993 and
from 1994 to 1999.
Two studies in Kentucky correlated breast cancer incidence
with county-level exposure to triazines. The latter was
estimated by jointly considering triazine levels in water
samples, the amount of corn crops grown and county-speciﬁc
pesticide use data. The ﬁrst of these studies (Kettles et al.,
1997) observed that in 1991 through 1992, the adjusted
incidence of breast cancer in the 24 counties with the greatest
estimated triazine exposure was nine percent higher than in
the 54 counties with the lowest exposure. In 1993–1994,
the corresponding ﬁgure was a 22% increase. In contrast, the
second study (Hopenhayn-Rich et al., 2002) observed a 2%
lower breast cancer incidence during 1993 through 1997 in
counties with the highest, compared with the lowest, estimated
atrazine exposures.
One additional ecologic study of breast cancer and atrazine
(and cyanazine), in groupings of electoral wards in two districts
of England (Muir et al., 2004), was not considered because the
incidence rates varied across geographic groupings to such an
implausibly large degree, more than 24-fold, that chance must
have been exerting a strong inﬂuence. This variability was
probably due to the evaluation of small geographic areas and
the narrow window of time (1989 through 1991).
In summary, the association between exposure to atrazine or
triazines exposure and breast cancer was largely null. These
results are consistent with conclusions reached by various
regulatory agencies that atrazine or the triazines are ‘‘un-
classiﬁable as to carcinogenicity’’ (IARC, 1999) or that
atrazine is not likely to be carcinogenic (USEPA, 2003b,
2006) with regard to any cancer.
CONCLUSIONS
Using the framework outlined by Adami et al. (2011),
atrazine is placed within the lower left hand quadrant of the
framework categorical diagram (Fig. 6), which classiﬁes
atrazine in Category 4 unlikely. This conclusion is based upon
(1) epidemiological evidence suggesting that exposure to
atrazine is not associated with the occurrence of breast cancer
in women and (2) the lack of a plausible mode of action for the
occurrence of atrazine-related breast cancer in women.
This classiﬁcation took into account a substantial body of
literature on the mode of action plus the absence of positive
epidemiological evidence, recognizing that the majority of the
relevant studies were underpowered and might not detect small
changes in breast cancer incidence. This conclusion is
consistent with previous schemes for the classiﬁcation of the
carcinogenic potential of atrazine in humans (Table 3). These
assessments collectively have taken into account the animal
and all the human epidemiology evidence (IARC, 1999;
USEPA, 2003b, 2006). However, the integrated approach
developed by Adami et al. (2011) and used here provides
explicit guidance on how to weigh study quality and how to
integrate toxicological and epidemiology evidence. This
approach has the additional advantage of qualitatively
characterizing the uncertainty associated with any inference
of causality and identifying whether additional mechanistic
studies or epidemiological research would be more effective in
reducing uncertainty.
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